Compare XCUR & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XCUR | PMI |
|---|---|---|
| Founded | 2011 | 1981 |
| Country | United States | United States |
| Employees | N/A | 75 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 14.1M |
| IPO Year | 2017 | N/A |
| Metric | XCUR | PMI |
|---|---|---|
| Price | $2.60 | $0.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.9K | ★ 31.4M |
| Earning Date | 03-25-2026 | 06-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.71 | $0.11 |
| 52 Week High | $9.50 | $13.68 |
| Indicator | XCUR | PMI |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 36.52 |
| Support Level | $1.71 | $0.15 |
| Resistance Level | $3.40 | $0.27 |
| Average True Range (ATR) | 0.38 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 39.60 | 6.81 |
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.